Medicenna Therapeutics【MDNA】銘柄情報

Medicenna Therapeutics Corp (MDNA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.43

( - )

買値

0.43

売値

0.435

出来高

16,034

0.43 日の範囲 0.445

0.41 52 週間の範囲 1.97

時価総額

39.689M

前日終値

0.43

始値

0.445

時刻

1000

0.43

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 111,869

発行済株式数

92,300,201

配当利回り

PER

-2.65

1 株当たり利益 (EPS)

-0.16

歳入

純利益

-12.99M

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for... Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.medicenna.com

本社

Toronto, Canada

設立

Medicenna Therapeutics Corp is listed in the Healthcare sector of the トロント証券取引所 with ticker MDNA. The last closing price for Medicenna Therapeutics was $0.43. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.41 to $ 1.97.

Medicenna Therapeutics currently has 92,300,201 shares in issue. The market capitalisation of Medicenna Therapeutics is $39.69 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -2.65.

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX:...

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may...

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28...

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and...

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on...

Medicenna Announces the Launch of a Marketed Public Offering of Securities

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and...

Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment;...

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and...

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna”...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.43	0.445	0.41	55548	0.41621359	CS
4	-0.03	-6.52173913043	0.46	0.475	0.41	74938	0.43441502	CS
12	-0.22	-33.8461538462	0.65	0.74	0.41	106005	0.54801205	CS
26	-0.57	-57	1	1.08	0.41	110562	0.73001068	CS
52	-0.46	-51.6853932584	0.89	1.97	0.41	92004	0.95605981	CS
156	-0.35	-44.8717948718	0.78	2.98	0.215	83753	1.27625154	CS
260	-4.09	-90.4867256637	4.52	4.7	0.215	68413	1.45096931	CS